BIO Targets 340B Hospital Acquisitions Of Oncology Practices In Study
This article was originally published in The Pink Sheet Daily
Executive Summary
In an effort to support its claim that the 340B drug discount program is being used by hospitals to generate profits, the Biotechnology Industry Organization released a study finding use of 340B drugs at physician-based oncology practices grew significantly after they were acquired by hospitals.